Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy

Ikram A. Burney, Ross J. Maxwell, Stan B. Field, Cheryl L. McCoy, John R. Griffiths

Research output: Contribution to journalArticle

7 Citations (Scopus)


A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45% reduction in mean arterial blood pressure (MABP) and a 40-60% reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20% reduction in MABP led to a 50-60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.

Original languageEnglish
Pages (from-to)367-371
Number of pages5
JournalActa Oncologica
Issue number3
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Fingerprint Dive into the research topics of 'Effect of vasoactive drugs on tumour blood flow as determined by <sup>2</sup>h nuclear magnetic resonance spectroscopy'. Together they form a unique fingerprint.

  • Cite this